Loading...
•
Nov 30, 2025
Simulations Plus Q1 2026 Earnings Report
Simulations Plus reported its Q1 2026 results with revenue slightly down and continued profitability.
Key Takeaways
Simulations Plus delivered a modestly profitable Q1 2026, with strong service revenue offsetting a decline in software sales. The company reaffirmed its full-year guidance and emphasized growth opportunities in AI-powered drug development.
Revenue by Segment
Forward Guidance
Simulations Plus reaffirmed its fiscal 2026 guidance, projecting flat to modest revenue growth and stable margins, with a continued focus on expanding AI-driven solutions.
Positive Outlook
- Reaffirmed FY2026 revenue guidance of $79M–$82M
- Strong bookings across software and services
- Improved client funding environment
- Annual software price increases expected to contribute
- Poised for AI-enabled drug development leadership
Challenges Ahead
- Software revenue declined 17% YoY in Q1
- Adjusted EBITDA margin dropped from 24% to 19%
- Adjusted net income fell YoY
- Ongoing softness in clinical operations revenue
- Reorganization and M&A costs impacted previous performance
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...